Climb Bio

We believe elevating relationships leads to more meaningful insights, better answers, and ultimately, to more inspired medicines for patients

[Climb Bio @ClimbBio]

Later today $CLYM will be participating in a fireside chat with @MorganStanley 

🔗 Tune in to learn more about the trail ahead: https://t.co/cYR5cFdogX 

#ClimbBio #TimeToClimb #Immunology #Autoimmune #Nephrology #BCell

[Climb Bio @ClimbBio]

#ICYMI: Initial Phase 1 data for CLYM116 presented on Sept 3 

🔗 Watch the replay: https://t.co/0s5ewfT8xr

[Climb Bio @ClimbBio]

Later today, @Susan Altschuller, Ph.D., MBA will be participating in a fireside chat with @Wells Fargo
🔗 Tune in to learn more about the trail ahead: https://t.co/cYR5cFdogX 
#ClimbBio #TimeToClimb #Immunology #Autoimmune #Nephrology #BCell

[Climb Bio @ClimbBio]

TODAY: Initial Phase 1 data for CLYM116
📅 September 3 | 8:00 AM
🎙️ Live webcast: https://t.co/0s5ewfT8xr

[Climb Bio @ClimbBio]

The Trail Ahead: September ⛰️

Upcoming events:
🔷 R&D Spotlight: CLYM116 Initial Phase 1 Data | September 3
🔷 Wells Fargo Healthcare Conference | September 9
🔷 Morgan Stanley | September 16

🔗 Learn more: https://t.co/u0KhjKn31v

[Climb Bio @ClimbBio]

The Trail Ahead ⛰️

Several key waypoints are coming into view:
🔷 Sept 3: CLYM116 R&D Spotlight on Sept 3 
Register for the event here: https://t.co/0s5ewfT8xr 

Budo data in Q4: 
🔷 Phase 2 pMN 
🔷 Phase 1b SLE 
🔷 Phase 1b ITP

[Climb Bio @ClimbBio]

We recently shared that the first IgAN patient was dosed with CLYM116 in a Phase 2 study.

Learn more about the CLYM116 program and our development plans at the upcoming R&D Spotlight Event on September 3. 

Register here: https://t.co/4FcQN4Le2z

[Climb Bio @ClimbBio]

Climb Bio is proud to support the inaugural World MN Day and the effort to amplify patient voices

🩵 Learn more about World MN Day from NephCure: https://t.co/6f0aYmk3kl

#WorldMNDay #MembranousNephropathy #RareDisease #KidneyDisease #MNAwarenessDay #HopeForMN

[Climb Bio @ClimbBio]

$CLYM announced our next R&D Spotlight for September 3, where we'll share initial Phase 1 data from CLYM116 and discuss our development strategy.

Learn more in our 2Q26 earnings release: https://t.co/x6fYeHXE7k

[Climb Bio @ClimbBio]

Thank you to the #ITP and #IgAN communities for two impactful conferences. We appreciated the opportunity to connect with patients, care partners, advocates, and healthcare professionals, and to continue learning from the community at the heart of progress in both diseases.

[Climb Bio @ClimbBio]

This weekend, $CLYM will be attending: 

📍 PDSA ITP Conference | Salt Lake City
📍 SPARK IgAN Conference | Atlanta

We look forward to listening, learning and engaging with the ITP and IgAN communities. #ITP #IgAN #PatientAdvocacy

[Climb Bio @ClimbBio]

CLYM116 is an investigational anti-APRIL monoclonal antibody with a recycling degrader “sweeper” mechanism of action, an approach designed to both block APRIL from binding to its receptors and promote APRIL degradation

🔗 https://t.co/VrZF1TBobt

[Climb Bio @ClimbBio]

The Trail Ahead ⛰️

At the end of July, Climb Bio will attend:
🔷 PDSA ITP Conference | July 24–26 | Salt Lake City
🔷 SPARK IgAN Conference | July 24–26 | Atlanta

We look forward to listening, learning and connecting.

🔗 https://t.co/Hq4X2CYwxK | https://t.co/skYePQeXTL

[Climb Bio @ClimbBio]

Thank you to @Wedbush for convening an important conversation on membranous nephropathy.
Yesterday, $CLYM CMO Edgar Charles joined  Dr. Sagar Nigwekar of Mass. General Hospital for a panel on the evolving treatment landscape, unmet need, and role of clinical research in pMN

[Climb Bio @ClimbBio]

CD19’s broad expression across the B-cell lineage may enable deeper, more durable depletion of B-cells and pathogenic autoantibodies, while preserving protective antibody responses mediated by long-lived plasma cells

🔗 https://t.co/7cczsf3Dq6

[Climb Bio @ClimbBio]

The Trail Ahead: July ⛰️
We’re continuing our data-rich 2026, with initial Ph1 data from CLYM116 in HVs expected late summer.
Along the route: continued execution across CLYM116 and budoprutug, plus engagement with the ITP and IgAN communities.

🔗 https://t.co/VNGtAtm4CY

[Climb Bio @ClimbBio]

#ICYMI: Last month, Climb Bio announced initial Phase 1b data demonstrating on-target clinical activity for budoprutug in ITP 

📈 View the poster: https://t.co/cjCTYgbbDo

[Climb Bio @ClimbBio]

We left the @nephcure Patient Summit inspired by the #RareKidneyDisease community

Key takeaway: progress in #IgAN and #pMN depends on partnership, and always with patients at the center

We are proud to support NephCure and this community

🔗 Learn more: https://t.co/OwpjLRV8Us

[Climb Bio @ClimbBio]

📍 New Orleans  

We’re at the @nephcure Patient Summit, connecting with patients, caregivers & advocates across the rare kidney disease community. We are proud to support and learn alongside this group. 

Learn more about NephCure: https://t.co/OwpjLRV8Us  

#NephCure #IgAN #pMN

[Climb Bio @ClimbBio]

We are proud to sponsor the @nephcure Patient and Youth Summits, bringing patients, caregivers, researchers & advocates together to learn, connect, and advance progress in #RareKidneyDisease 

👉 Learn more: https://t.co/ZdcdYuF9BX